Krystal Biotech Inc (NAS:KRYS)
$ 156.33 -6.5 (-3.99%) Market Cap: 4.46 Bil Enterprise Value: 4.12 Bil PE Ratio: 83.15 PB Ratio: 5.58 GF Score: 36/100

Krystal Biotech Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript

Mar 31, 2022 / 06:00PM GMT
Release Date Price: $66.54 (-0.54%)
Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst

So good afternoon and thank you for joining Guggenheim's Genomic Medicine and Rare Disease Conference, day one. I am Debjit Chattopadhyay, one of the analysts representing Guggenheim therapeutics team. My privilege to host Krystal's Chairman and CEO, Krish Krishnan.

Thank you very much for your time, Krish, and really appreciate this.

Krish Krishnan
Krystal Biotech, Inc. - Chairman & CEO

No, thanks for having me.

Questions & Answers

Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst

So let's get started. But first of all, obviously, congrats on your Phase 3 win with B-VEC, much-needed option for patients and families with DEB, in general. So do walk us through sort of the level of engagement that you've had with the FDA during the conduct or the inception of the clinical trial to the change of statistical analysis plan.

Krish Krishnan
Krystal Biotech, Inc. - Chairman & CEO

No

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot